A Two-part, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib (Part A) and the Effect of Fenebrutinib on the QT/QTc Interval in Healthy Participants (Part B) (P10-6.011)